JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB239020

Anti-CYP3A7 抗体

Anti-CYP3A7 antibody

Be the first to review this product! Submit a review

|

(1 Publication)

Rabbit Polyclonal CYP3A7 antibody. Suitable for IHC-P, ICC/IF and reacts with Human samples. Cited in 1 publication. Immunogen corresponding to Recombinant Fragment Protein within Human CYP3A7 aa 1-200.

別名を表示する

Cytochrome P450 3A7, CYPIIIA7, Cytochrome P450-HFLA, P450HLp2, CYP3A7

2 Images
Immunocytochemistry/ Immunofluorescence - Anti-CYP3A7 antibody (AB239020)
  • ICC/IF

Supplier Data

Immunocytochemistry/ Immunofluorescence - Anti-CYP3A7 antibody (AB239020)

HepG2 (human liver hepatocellular carcinoma cell line) cells stained for CYP3A7 using ab239020 at 1/100 dilution in ICC/IF, followed by Alexa Fluor 488® conjugated Goat Anti-Rabbit IgG (H+L).

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CYP3A7 antibody (AB239020)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CYP3A7 antibody (AB239020)

Paraffin-embedded human liver tissue stained for CYP3A7 with ab239020 at 1/100 dilution in immunohistochemical analysis.

Key facts

宿主種

Rabbit

クローン性

Polyclonal

アイソタイプ

IgG

キャリアフリー

No

交差種

Human

アプリケーション

IHC-P, ICC/IF

applications

免疫原

Recombinant Fragment Protein within Human CYP3A7 aa 1-200. The exact immunogen used to generate this antibody is proprietary information.

P24462

style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/20 - 1/200", "IHCP-species-notes": "<p></p>", "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "1/50 - 1/200", "ICCIF-species-notes": "<p></p>" } } }
style
left-column
style
left-column

出荷温度及び保存条件

製品の状態
Liquid
精製方法
Affinity purification Protein G
精製に関する特記事項
Purity greater than 95%.
バッファー組成
pH: 7.4 Preservative: 0.03% Proclin 300 Constituents: PBS, 50% Glycerol (glycerin, glycerine)
出荷温度
Blue Ice
短期保存期間
1-2 weeks
短期保存温度
+4°C
長期保存温度
-20°C
分注に関する情報
Upon delivery aliquot
保管に関する情報
Avoid freeze / thaw cycle
style
left-column

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

CYP3A7 also known as cytochrome P450 3A7 is an enzyme weighing approximately 57 kDa and belongs to the cytochrome P450 superfamily. This enzyme primarily facilitates the oxidation of various substrates including steroids fatty acids and xenobiotics. CYP3A7 expression is largely found in fetal liver tissue but shows decreased levels after birth. As part of the cytochrome P450 family CYP3A7 plays an important role in metabolic processes that modify and clear compounds from the body.
Biological function summary

CYP3A7 acts on endogenous and exogenous molecules influencing steroid metabolism and drug catabolism. This enzyme acts individually rather than as part of a larger enzyme complex. Its function contributes significantly to the metabolism of retinoic acid and other steroid hormones during fetal development. The enzyme's substrate specificity enables it to play a role in modulating biological availabilities of several substances during prenatal human development.

Pathways

CYP3A7's enzymatic activity integrates into the retinoic acid metabolism and steroid hormone biosynthesis pathways. It's actively involved in processing compounds needed for proper fetal growth and development such as all-trans-retinoic acid. Its relatives like CYP3A4 and CYP3A5 perform similar roles in adults showing high homology and overlapping substrate ranges reflecting their functional association within these pathways.

Researchers link CYP3A7 to alterations in drug metabolism affecting pharmacokinetics and therapeutic outcomes. For instance the enzyme's atypical activity can influence glucocorticoid metabolism connecting it to disorders like congenital adrenal hyperplasia. CYP3A7's function can also interact with proteins such as CYP21A2 further impacting steroidogenesis-related diseases. Understanding variations in CYP3A7 activity contributes to insights into certain congenital disorders and can guide personalized approaches in drug therapy.
style
left-column
style
left-column

製品プロトコール

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

ターゲットの情報

A cytochrome P450 monooxygenase involved in the metabolism of steroid hormones and vitamins during embryogenesis (PubMed : 11093772, PubMed : 12865317, PubMed : 14559847, PubMed : 17178770, PubMed : 9555064). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed : 11093772, PubMed : 12865317, PubMed : 14559847, PubMed : 17178770, PubMed : 9555064). Catalyzes the hydroxylation of carbon-hydrogen bonds. Metabolizes 3beta-hydroxyandrost-5-en-17-one (dehydroepiandrosterone, DHEA), a precursor in the biosynthesis of androgen and estrogen steroid hormones (PubMed : 17178770, PubMed : 9555064). Exhibits high catalytic activity for the formation of hydroxyestrogens from estrone (E1), particularly D-ring hydroxylated estrone at the C16-alpha position (PubMed : 12865317, PubMed : 14559847). Mainly hydroxylates all trans-retinoic acid (atRA) to 4-hydroxyretinoate and may play a role in atRA clearance during fetal development (PubMed : 11093772). Also involved in the oxidative metabolism of xenobiotics including anticonvulsants (PubMed : 9555064).
See full target information CYP3A7
style
left-column

文献 (1)

Recent publications for all applications. Explore the full list and refine your search

Frontiers in pharmacology 15:1336282 PubMed38576477

2024

PPARδ agonist protects against osteoarthritis by activating AKT/mTOR signaling pathway-mediated autophagy.

Applications

Unspecified application

Species

Unspecified reactive species

Guantong Sun,Xiaodong Li,Pengcheng Liu,Yao Wang,Cheng Yang,Shuhong Zhang,Lei Wang,Xiaoqing Wang
View all publications
style
left-column
style
left-column
style
right-column

代替製品

Primary Antibodies

AB169764

Anti-CYP3A7 antibody [EPR10650(2)(B)]

RabMAb|Recombinant

Western blot - Anti-CYP3A7 antibody [EPR10650(2)(B)] (AB169764)

  • 0
  • 0

組合せ製品

Primary Antibodies

AB124921

Anti-Cytochrome P450 3A4/CYP3A4 antibody [EPR6202]

RabMAb|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Cytochrome P450 3A4/CYP3A4 antibody [EPR6202] (AB124921)

  • 4
  • 1
Primary Antibodies

AB221547

Anti-ZO1 tight junction protein antibody [EPR19945-296]

20ul selling size|RabMAb|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-ZO1 tight junction protein antibody [EPR19945-296] (AB221547)

  • 5
  • 6
Primary Antibodies

AB108624

Anti-CYP3A5 antibody [EPR4396]

RabMAb|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CYP3A5 antibody [EPR4396] (AB108624)

  • 0
  • 0
Primary Antibodies

AB182126

Anti-PKC delta antibody [EPR17075]

KO Validated|RabMAb|Recombinant|20ul selling size

Immunocytochemistry/ Immunofluorescence - Anti-PKC delta antibody [EPR17075] (AB182126)

  • 4
  • 7

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。
保証に関する詳細については利用規約をご確認ください。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com